The Forgotten Middle:Where AI Must Go Next in Clinical Trials

The industry has raced to apply AI at the bookends of the trial lifecycle — protocol design and regulatory submission. But the vast operational territory in between remains starved of innovation, quietly consuming the time, attention, and expertise of the people who matter most.

If we are serious about AI's role in clinical trials, we must stop thinking in segments and start thinking in systems. The operational layer of a clinical trial is not a collection of disconnected tasks — it is a deeply interconnected process, and any AI solution that addresses only one node will inevitably create new bottlenecks adjacent to the ones it solves.

A holistic approach means building AI capabilities that span the operational continuum: from site activation and enrollment tracking through query management, risk-based monitoring, cross-functional visibility, and close-out. It means replacing asynchronous snapshots with a single, continuously-updated source of truth — one that every functional area reads from, rather than writes to independently.

It means giving clinical professionals the gift of time: time reclaimed from the manual, the repetitive, and the purely administrative — and returned to the analytical, the relational, and the expert. A CRA whose site status reports are generated automatically is a CRA who can spend that hour thinking. A project manager whose cross-functional dashboard updates in real time is a project manager who can anticipate, rather than react.

The forgotten middle deserves to be found. And when it is — trials will run faster, data will be cleaner, teams will practice at the top of their expertise, and patients will benefit sooner...

Continue reading to explore the full capabilities of Aurelyn AI and unlock the next generation of clinical intelligence.

Keep Reading